Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 1/2012

01-03-2012 | Lymphomas (L Gordon, Section Editor)

Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments

Authors: Tara Bloom, BA, MS-II, Timothy M. Kuzel, MD, Christiane Querfeld, MD, PhD, Joan Guitart, MD, Steven T. Rosen, MD, FACP

Published in: Current Treatment Options in Oncology | Issue 1/2012

Login to get access

Opinion statement

Treatment regimens of patients with CTCL vary widely based on clinician preference and patient tolerance. Skin directed therapies are recommended for patients with early stage IA and IB MF, with combinations used in refractory cases. While no regimen has been proven to prolong survival in advanced stages, immunomodulatory regimens should be used initially to reduce the need for cytotoxic therapies. In more advanced stages of disease, treatment efforts should strive for palliation and improvement of quality of life. With many new therapies and strategies on the horizon, the future looks promising for CTCL patients. Unfortunately, other than allogeneic HCT, there are no potential curative therapies for CTCL. Clinical trials are currently underway to identify new therapies to improve quality of life for patients, and researchers are hard at work to identify novel pathways and genes for prognostication and as targets for therapies. Importantly, collaborative clinical trials to enhance rates of accrual need to be conducted, and improved interpretation of data via standardizing end points and response criteria should be an emphasis. Recently, the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) met to develop consensus guidelines to facilitate collaboration on clinical trials. These proposed guidelines consist of: recommendations for standardizing general protocol design; a scoring system for assessing tumor burden in skin, lymph nodes, blood, and viscera; definition of response in skin, nodes, blood, and viscera; a composite global response score; and a definition of end points. Although these guidelines were generated by consensus panels, they have not been prospectively or retrospectively validated through analysis of large patient cohorts.
Literature
1.
Bradford P, Devesa S, Anderson W, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.PubMedCrossRef
2.
Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240–4.PubMedCrossRef
3.
Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112:3082–7.PubMedCrossRef
4.
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.PubMedCrossRef
5.
Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker fordiagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115(6):885–92.PubMedCrossRef
6.
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cellsby enhanced recruitment of effector T cells. Int Immunol. 2005;17(2):133–44.PubMedCrossRef
7.
Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382–8.PubMedCrossRef
8.
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumorcells by enhanced recruitment of effector T cells. Int Immunol. 2005;17(2):133–44.PubMedCrossRef
9.
Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11(3):299–308.PubMedCrossRef
10.
Kamstrup MR, Gjerdrum LM, Biskup E, et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2010;116(14):2504–12.PubMedCrossRef
11.
Hu C, Dievart A, Lupien M, et al. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland developmentand induces mammary tumors. Am J Pathol. 2006;168(3):973–90.PubMedCrossRef
12.
Pinnix CC, Lee JT, Liu ZJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res. 2009;69(13):5312–20.PubMedCrossRef
13.
Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856–65.PubMedCrossRef
14.
Wozniak MB, Tracey L, Ortiz-Romero PL. Psoralen plus ultraviolet A +/− interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. Br J Dermatol. 2009;160(1):92–102.PubMedCrossRef
15.
Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006;20:333–42.PubMedCrossRef
16.
Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001;97:1056–62.PubMedCrossRef
17.
Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009;129(5):1165–73.PubMedCrossRef
18.
Jones CL, Wain EM, Chu CC, et al. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation. J Invest Dermatol. 2010;130(4):1116–25.PubMedCrossRef
19.
Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancementof sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147(4):443–9.PubMedCrossRef
20.•
Rovedo M, Krett N, Rosen S. Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of Enzastaurin. J Invest Dermatol. 2011;131:1442–9.PubMedCrossRef
21.
Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006;126:1641–7.PubMedCrossRef
22.
Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer. 2006;42:1014–30.PubMedCrossRef
23.•
van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome. Blood. 2009;113(1):127–36.PubMedCrossRef
24.
Booken N, Gratchev A, Utikal J, et al. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2008;22:393–9.PubMedCrossRef
25.
Vermeer MH, Van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res. 2008;68:2689–98.PubMedCrossRef
26.•
Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–71.PubMedCrossRef
27.•
Laharanne E, Oumouhou N, Bonnet F, et al. Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes. J Invest Dermatol. 2010;130(6):1707–18.PubMedCrossRef
28.
Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol. 2010;23(4):547–58.PubMedCrossRef
29.
Navas IC, Ortiz-Romero PL, Villuendas R, et al. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol. 2000;156:1565–72.PubMedCrossRef
30.
Carbone A, Bernardini L, Valenzano F, et al. Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF. Genes Chromosomes Cancer. 2008;47:1067–75.PubMedCrossRef
31.
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–9.PubMedCrossRef
32.
Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145:928–37.PubMedCrossRef
33.
Klemke CD, Brenner D, Weiss EM, et al. Lack of T-Cell receptor–induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-Cell lymphoma cells from activation-induced cell death. Cancer Res. 2009;69(10):4175–83. Epub 2009 May 12.PubMedCrossRef
34.
Litvinov IV, Jones DA, Sasseville D, et al. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res. 2010;16(7):2106–14. Epub 2010 Mar 16.PubMedCrossRef
35.
Lansigan F, Foss F. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs. 2010;70(3):273–86.PubMedCrossRef
36.
Querfeld C, Rosen S, Kuzel T, et al. Long-term follow-up of patients with early-stage cutaneous T-Cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141:305–11.PubMedCrossRef
37.
Herrmann JJ, Roenigk Jr HH, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1077–88.PubMed
38.
Hönigsmann H, Tanew A. Photo(chemo)therapy for cutaneous T-cell lymphoma. In: Krutmann J, Hönigsmann H, Elmets CA, editors. Dermatologic phototherapy and photodiagnostic methods. 2nd ed. Heidelberg: Springer; 2009. p. 135–49.CrossRef
39.
Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer. 2006;42:1014–30.PubMedCrossRef
40.
Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed. 2011;27(2):68–74.PubMedCrossRef
41.
Rosen ST, Querfeld C, Kuzel TM, Guitart J. Cutaneous T-Cell lymphomas: a guide for the community oncologist, 2nd edn. 2008.
42.
Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(8):949–54.PubMedCrossRef
43.
Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–73.PubMedCrossRef
44.
45.
Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160(6):1299–307.PubMedCrossRef
46.
Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene treatment for patients with refractory or persistent early stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49:801–15.PubMedCrossRef
47.
Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–32.PubMedCrossRef
48.
Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50(4):600–7.PubMedCrossRef
49.
Navi D, Riaz N, Levin YS, Sullivan NC, et al. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol. 2011;147(5):561–7.PubMedCrossRef
50.
Introcaso CE, Micaily B, Richardson SK, et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome. J Am Acad Dermatol. 2008;58(4):592–5.PubMedCrossRef
51.
Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71.PubMed
52.
Assaf C, Bagot M, Dummer R. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006;155:261–6.PubMedCrossRef
53.
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 2002;100(4):1399–403.PubMedCrossRef
54.
Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005;106(2):454–7.PubMedCrossRef
55.
Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol. 1994;46:179–83.PubMedCrossRef
56.
Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997;33 suppl 1:S34–6.PubMedCrossRef
57.•
Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-celllymphoma. J Clin Oncol. 2010;28(11):1870–7. Epub 2010 Mar 8.
58.
59.
Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376–88.PubMed
60.
Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther. 2003;16:337–46.PubMedCrossRef
61.
Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg. 2003;7:3–7.PubMedCrossRef
62.
Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci. 2003;28:81–9.PubMedCrossRef
63.•
Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352–404.PubMedCrossRef
64.
Bisaccia E, Vonderheid EC, Geskin L. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. Br J Dermatol. 2009;161(1):167–9.PubMedCrossRef
65.
Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photophoresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43:54–60.PubMedCrossRef
66.
Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunotherapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138:1054–60.PubMedCrossRef
67.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.PubMedCrossRef
68.
69.
Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98(9):2865–8.PubMedCrossRef
70.•
Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485.PubMedCrossRef
71.
Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410–7.PubMedCrossRef
72.
Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J. 2007;13:30–9.PubMedCrossRef
73.
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–9.PubMedCrossRef
74.
Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125:1045–52.PubMedCrossRef
75.
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat for refractory cutaneous T cell lymphoma. Blood. 2007;109:31–9.PubMedCrossRef
76.
Wozniak MB, Villuendas R, Bischoff JR, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica. 2010;95(4):613–21.PubMedCrossRef
77.
Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–64.PubMedCrossRef
78.
Avilés A, Nambo MJ, Neri N, et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. Cancer Biother Radiopharm. 2007;22(6):836–40.PubMedCrossRef
79.
Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95:569–75.PubMedCrossRef
80.
Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005;75:136–45.PubMedCrossRef
81.
Stadler RKA, Luger T, Sterry W. Prospective, randomized, multicentre clinical trial on the use of interferon a-2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II. J Clin Oncology, ASCO Annual Meeting Proceedings Part I 2006;24 (Suppl.):18s. (abstr 7541).
82.
Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):395–407.PubMedCrossRef
83.
Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009;50:1969–76.PubMedCrossRef
84.
Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431–9.PubMed
85.
Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. J Clin Pathol. 1994;47:313–7.PubMedCrossRef
86.
Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature. 1998;332:323–7.CrossRef
87.
Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral T-cell Lymphoma. Haematologica. 2007;92:566–7.PubMedCrossRef
88.
89.
Dyer MJ, Hale G, Hayhoe FG, et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431–9.PubMed
90.
Dearden CE, Matutes E, Cazin B, et al. High remission rate in prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–6.PubMedCrossRef
91.
Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell Lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–23.PubMedCrossRef
92.
Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205–13.PubMedCrossRef
93.
Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell Lymphoma. Blood. 2004;103:2920–4.PubMedCrossRef
94.
Mijovic A, Abdallah A, Pearce L, et al. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens. Br J Haematol. 2008;142:444–52.PubMedCrossRef
95.
Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92:784–94.PubMedCrossRef
96.
Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fugoides/Sezary syndrome. Blood. 2003;101:4267–72.PubMedCrossRef
97.
Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology. 2004;208:281–3.PubMedCrossRef
98.
Porcu P, Baiocchi RA, Lee J, Lin TS, Blum K, Grady T, et al. Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: preliminary results [abstract]. J Clin Oncol. 2006;24((suppl 18S)):7594.
99.
Querfeld C, Kuzel TM, Guitart J, et al. Preliminary results of a phase II study of CC-5013 (Lenalidomide, Revlimid™) in patients with cutaneous T-cell lymphoma. Blood. 2005;106:936a–7a.
100.•
Querfeld C, Kuzel T, Guitart J, et al. Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. Hematology Meeting Reports. 2009;3(1):103–5.
101.
Kaye FJ, Bunn Jr PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784–90.PubMedCrossRef
102.
Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl- 10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6(9):3493–8.PubMed
103.
O’Connor OA. Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol. 2006;18(6):591–7.PubMedCrossRef
104.•
O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357–64.PubMedCrossRef
105.
Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–7.PubMedCrossRef
106.
Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001;13:514–21.PubMedCrossRef
107.
Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7:51–8.PubMedCrossRef
108.
Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603–6.PubMed
109.
Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104:2437–41.PubMedCrossRef
110.
Von Hoff DD, Dahlberg S, Hartstock RJ, et al. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst. 1990;82(16):1353–5.CrossRef
111.
Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol. 1992;10(12):1907–13.PubMed
112.
Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993–1001.PubMedCrossRef
113.•
Querfeld C, Rosen ST, Guitart J, et al. Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/SezarySyndrome: Correlation with O6-Methylguanine-DNA Methyltransferase andMismatch Repair Proteins. Clin Cancer Res. 2011;17(17):5748–54.PubMedCrossRef
114.
Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 1996;56:5375–9.PubMed
115.
Reni M, Mason W, Zaja F, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004;40:1682–8.PubMedCrossRef
116.
Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66.PubMed
117.
Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871–4.PubMedCrossRef
118.
Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T cell lymphoma. Cancer. 1999;86:1368–76.PubMedCrossRef
119.
Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998;31(5–6):583–8.PubMed
120.
Mebazaa A, Dupuy A, Rybojad M, Mouly F, Moulonguet I, Vignon-Pennamen MD, Rivet J, Janin A, Lebbé C, Dubertret L, Morel P, Bachelez H, Brice P. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Hematol J. 2005;5(7):553–8.PubMedCrossRef
121.
Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597–604.PubMedCrossRef
122.
Wu PA, Kim YH, Lavori PW, et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant. 2009;15:982–90.PubMedCrossRef
123.•
Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–9.PubMedCrossRef
124.
Carrié E, Buzyn A, Fraitag S, et al. Transformed juvenile-onset mycosis fungoides: Treatment by bone marrow transplantation with graft-versus-lymphoma effect. Ann Dermatol Venereol. 2007;134:471–6.PubMedCrossRef
125.
Gabriel IH, Olavarria E, Jones RR, et al. Graft versus lymphoma effect after early relapse following reduced intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant. 2007;40:401–3.PubMedCrossRef
126.
Soligo D, Ibatici A, Berti E, et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant. 2003;31:663–6.PubMedCrossRef
127.
Burt RK, Guitart J, Traynor A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft-versus-tumor effect. Bone Marrow Transplant. 2000;25:111–3.PubMedCrossRef
128.
Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. J Clin Oncol. 2005;23:6163–71.PubMedCrossRef
129.
Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597–604.PubMedCrossRef
130.
Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365–72.PubMedCrossRef
131.
BioCryst Pharmaceuticals. Forodesine in the treatment of cutaneous T-cell lymphoma [ClinicalTrials.gov identifier NCT00501735]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov
132.
Rider DA, Havenith CEG, de Ridder R, Schuurman J, Favre C, Cooper JC, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007;67:9945–53.PubMedCrossRef
133.•
Metadata
Title
Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments
Authors
Tara Bloom, BA, MS-II
Timothy M. Kuzel, MD
Christiane Querfeld, MD, PhD
Joan Guitart, MD
Steven T. Rosen, MD, FACP
Publication date
01-03-2012
Publisher
Current Science Inc.
Published in
Current Treatment Options in Oncology / Issue 1/2012
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-011-0179-8

Other articles of this Issue 1/2012

Current Treatment Options in Oncology 1/2012 Go to the issue

Head and Neck Cancer (T Day, Section Editor)

Current Treatment Options for Metastatic Head and Neck Cancer

Head and Neck Cancer (T Day, Section Editor)

Recurrent Salivary Gland Cancer

Lymphomas (L Gordon, Section Editor)

Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

Lymphomas (L Gordon, Section Editor)

Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Parathyroid Carcinoma: Update and Guidelines for Management

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits